Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-03-12
DOI
10.3389/fonc.2020.00343
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
- (2019) Alice Guazzelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
- (2019) Maria J Disselhorst et al. Lancet Respiratory Medicine
- Enhancing Dendritic cell Therapy in Solid Tumors with Immune Modulating Conventional Treatment
- (2019) R.A. Belderbos et al. Molecular Therapy-Oncolytics
- Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
- (2019) Prasad S. Adusumilli et al. JOURNAL OF CLINICAL ONCOLOGY
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
- (2019) Raffit Hassan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
- (2019) Nadine L de Boer et al. BMJ Open
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma
- (2019) Raffit Hassan et al. CLINICAL CANCER RESEARCH
- Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)
- (2019) Morihito Okada et al. CLINICAL CANCER RESEARCH
- CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
- (2019) Andre Kunert et al. Journal for ImmunoTherapy of Cancer
- A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
- (2019) Robert A. Belderbos et al. Translational Lung Cancer Research
- LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2019) S Popat et al. ANNALS OF ONCOLOGY
- LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
- (2019) S A Burgers et al. ANNALS OF ONCOLOGY
- 1843OSAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial
- (2019) Y Metaxas et al. ANNALS OF ONCOLOGY
- Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
- (2019) Giovanni L Ceresoli et al. LANCET ONCOLOGY
- Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge
- (2018) Luana Calabrò et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
- (2018) Nobukazu Fujimoto et al. Clinical Lung Cancer
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of intracavitary therapies in the treatment of malignant pleural mesothelioma
- (2018) Pietro Bertoglio et al. Journal of Thoracic Disease
- A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.
- (2018) Kwang-Yu Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitor and radiation therapy in malignant pleural mesothelioma.
- (2018) Seiji Matsumoto et al. JOURNAL OF CLINICAL ONCOLOGY
- DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
- (2018) Anna K. Nowak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
- (2018) Anne S. Tsao et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- Scientific Advances and New Frontiers in Mesothelioma Therapeutics
- (2018) Luciano Mutti et al. Journal of Thoracic Oncology
- CBMT-29. INDUCTION OF AUTOPHAGY FOLLOWING TTFIELDS APPLICATION SERVES AS A SURVIVAL MECHANISM MEDIATED BY AMPK ACTIVATION
- (2018) Anna Shteingauz et al. NEURO-ONCOLOGY
- Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
- (2018) Mandy van Gulijk et al. Frontiers in Immunology
- Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
- (2018) Anne Huber et al. Frontiers in Immunology
- Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
- (2017) Emma Beddowes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
- (2017) Federica Grosso et al. JOURNAL OF CLINICAL ONCOLOGY
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
- (2017) Christian Manegold et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Oncolytic Viral Therapy for Mesothelioma
- (2017) Daniel F. Pease et al. Frontiers in Oncology
- Oncolytic viruses: finally delivering
- (2016) Leonard W Seymour et al. BRITISH JOURNAL OF CANCER
- CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
- (2016) M. Betti et al. CANCER LETTERS
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
- (2016) Andreas Rimner et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes
- (2016) Wieneke A. Buikhuisen et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma
- (2016) Yoshie Yoshikawa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) P. Baas et al. ANNALS OF ONCOLOGY
- Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer
- (2015) Jill A. Ohar et al. CANCER RESEARCH
- Targeting immune checkpoints: New opportunity for mesothelioma treatment?
- (2015) Elly Marcq et al. CANCER TREATMENT REVIEWS
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study
- (2015) Marco Lo Iacono et al. Journal of Thoracic Oncology
- CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
- (2015) G. Eilers et al. MOLECULAR CANCER THERAPEUTICS
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer
- (2015) Manish R. Patel et al. Oncotarget
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
- (2014) S Zhou et al. BRITISH JOURNAL OF CANCER
- Asbestos: use, bans and disease burden in Europe
- (2014) Takashi Kameda et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
- (2014) G. Guo et al. CANCER RESEARCH
- Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma
- (2014) Anne S. Tsao et al. Clinical Lung Cancer
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- (2014) Aaron Scott Mansfield et al. Journal of Thoracic Oncology
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
- (2014) Mariam Jamal-Hanjani et al. PLOS BIOLOGY
- Therapies currently in Phase II trials for malignant pleural mesothelioma
- (2013) Giulia Pinton et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
- (2013) Giulia Pinton et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
- (2013) Sophie Papa et al. Journal of Thoracic Oncology
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Deciphering Signatures of Mutational Processes Operative in Human Cancer
- (2013) Ludmil B. Alexandrov et al. Cell Reports
- Dendritic cell-based immunotherapy in mesothelioma
- (2012) Robin Cornelissen et al. Immunotherapy
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
- (2012) Loïc Lang-Lazdunski et al. Journal of Thoracic Oncology
- Malignant Pleural Mesothelioma: From the Bench to the Bedside
- (2012) P. Astoul et al. RESPIRATION
- A Trial of Intrapleural Adenoviral-mediated Interferon-α2b Gene Transfer for Malignant Pleural Mesothelioma
- (2011) Daniel H. Sterman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
- (2011) Tom Treasure et al. LANCET ONCOLOGY
- Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
- (2011) Giovanni L. Ceresoli et al. LUNG CANCER
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
- (2010) Joost P. Hegmans et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Gene Therapy for Mesothelioma and Lung Cancer
- (2010) Anil Vachani et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
- (2010) Barbara Delage et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
- (2010) Sarita Dubey et al. Journal of Thoracic Oncology
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice
- (2008) S. P. Dineen et al. CANCER RESEARCH
- Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients
- (2008) Raja M. Flores et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More